Selected article for: "active site and SARS cov"
Author: Changhai Lei; Wenyan Fu; Kewen Qian; Tian Li; Sheng Zhang; Min Ding; Shi Hu
Title: Potent neutralization of 2019 novel coronavirus by recombinant ACE2-Ig
  • Document date: 2020_2_2
    • ID: aeuy92bx_4
    Snippet: Based on the receptor function of ACE2 for coronavirus, we hypothesis that ACE2 fusion protein may have neutralization potential for coronavirus, especially the 2019-nCoV. To further evaluated the therapeutic potential of ACE2, fusion protein (ACE2-Ig) consisting of the extracellular domain of human ACE2 linked to the Fc domain of human IgG1 was constructed and generated ( Fig. 1 ). An ACE2 variant (HH/NN) in which two active-site histidines (res.....
    Document: Based on the receptor function of ACE2 for coronavirus, we hypothesis that ACE2 fusion protein may have neutralization potential for coronavirus, especially the 2019-nCoV. To further evaluated the therapeutic potential of ACE2, fusion protein (ACE2-Ig) consisting of the extracellular domain of human ACE2 linked to the Fc domain of human IgG1 was constructed and generated ( Fig. 1 ). An ACE2 variant (HH/NN) in which two active-site histidines (residues 374 and 378) have been altered to asparagines was also used in our study to reduce the catalytic activity. The fusion protein contain the ACE2 variant were termed as mACE2-Ig. The expression and purification methods were described in our previous reports 13, 14 . The affinities of the fusion proteins for SARS-CoV RBD and 2019-nCoV RBD were determined with BIAcore binding author/funder. All rights reserved. No reuse allowed without permission.

    Search related documents:
    Co phrase search for related documents
    • extracellular domain and fusion protein: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • extracellular domain and human IgG1 Fc domain: 1, 2, 3, 4, 5
    • extracellular domain and receptor function: 1, 2, 3
    • extracellular domain and therapeutic potential: 1, 2, 3, 4, 5, 6, 7
    • Fc domain and fusion protein: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • Fc domain and human IgG1 Fc domain: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • Fc domain and purification expression: 1
    • Fc domain and therapeutic potential: 1, 2, 3, 4
    • fusion protein and human IgG1 Fc domain: 1, 2
    • fusion protein and neutralization potential: 1, 2, 3
    • fusion protein and previous report: 1, 2, 3
    • fusion protein and purification expression: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19
    • fusion protein and receptor function: 1, 2, 3, 4, 5, 6, 7
    • fusion protein and therapeutic potential: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23
    • human IgG1 Fc domain and therapeutic potential: 1
    • neutralization potential and therapeutic potential: 1, 2, 3, 4, 5, 6
    • previous report and therapeutic potential: 1
    • purification expression and therapeutic potential: 1, 2, 3, 4
    • receptor function and therapeutic potential: 1, 2, 3, 4, 5, 6